FDA label
What is Baqsimi used for?
Baqsimi contains glucagon. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “BAQSIMI™ is indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Baqsimi?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Baqsimi, powder
Indications and Usage, quoted from the label by Sportpharm LLC (NDA210134). Cross-references to other label sections are left out.
BAQSIMI™ is indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes.
Source: DailyMed label, set id 32ba41fa-4158-40af-8cb2-03693c248994, version 1, effective June 19, 2026. NDC 85766-212, one of 3 listings for this product.
Questions
What is Baqsimi used for?
The FDA label says: “BAQSIMI™ is indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes.”
What drug class is Baqsimi?
FDA lists glucagon in the Antihypoglycemic Agent and Gastrointestinal Motility Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.
More on Baqsimi
- Is Baqsimi a controlled substance?Federal schedule
- Generic for BaqsimiFDA Orange Book
- Is Glucagon a controlled substance?Federal schedule
- Generic for Gvoke HypoPenFDA Orange Book
- Generic for Gvoke KitFDA Orange Book
- Generic for Gvoke PFSFDA Orange Book
- Antihypoglycemic Agents listFDA drug class
- Gastrointestinal Motility Inhibitors listFDA drug class
- NDC 0548-8351Baqsimi NDC record
- NDC 0548-8352Baqsimi NDC record
- NDC 85766-212Baqsimi NDC record